



NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. This summary includes the results of the August 2011 NCCN Trends™ Survey, which focused on Breast Cancer. This survey was sent to U.S. and International users of NCCN.org.

DEMOGRAPHICS


Distribution of Respondent Types (n = 2,370)



Q1. Do you treat or care for patients with Breast Cancer?
(n = 2,386)




Q2. For what percentage of your newly diagnosed, chemotherapy eligible breast cancer patients with stage I/II, ER+, HER2-, and pathologically node negative (pN0) disease, and tumor size greater than 0.5 cm was an Oncotype DX Breast Cancer Assay ordered in the past year? (n = 1,398)




Q2. For what percentage of your newly diagnosed, chemotherapy eligible breast cancer patients with stage I/II, ER+, HER2-, and pathologically node negative (pN0) disease, and tumor size greater than 0.5 cm was an Oncotype DX Breast Cancer Assay ordered in the past year?

By Geography†




By Practice Size†




†Note: Percentages may not total 100 because of rounding

Q2. For what percentage of your newly diagnosed, chemotherapy eligible breast cancer patients with stage I/II, ER+, HER2-, and pathologically node negative (pN0) disease, and tumor size greater than 0.5 cm was an Oncotype DX Breast Cancer Assay ordered in the past year?

By Practice Setting




By Specialty†




†Note: Percentages may not total 100 because of rounding

Q3. How familiar are you that consideration of Oncotype DX Breast Cancer Assay for breast cancer patients with stage I/II, ER+, HER2- disease, and tumor size greater than 0.5 cm with pN1mi (micrometastatic disease) is included in the NCCN Guidelines? (n = 1,437)†




By Geography




†Note: Percentages may not total 100 because of rounding

Q3. How familiar are you that consideration of Oncotype DX Breast Cancer Assay for breast cancer patients with stage I/II, ER+, HER2- disease, and tumor size greater than 0.5 cm with pN1mi (micrometastatic disease) is included in the NCCN Guidelines?

By Practice Size †




By Practice Setting



†Note: Percentages may not total 100 because of rounding


Q3. How familiar are you that consideration of Oncotype DX Breast Cancer Assay for breast cancer patients with stage I/II, ER+, HER2- disease, and tumor size greater than 0.5 cm with pN1mi (micrometastatic disease) is included in the NCCN Guidelines?

By Specialty†




†Note: Percentages may not total 100 because of rounding

Q4. Do you personally order the Oncotype DX Breast Cancer Assay for your breast cancer patients with stage I/II, ER+, HER2-, and pN1mi (micrometastatic disease)? (n = 1,430)




By Geography




Q4. Do you personally order the Oncotype DX Breast Cancer Assay for your breast cancer patients with stage I/II, ER+, HER2-, and pN1mi (micrometastatic disease)?

By Practice Size




By Practice Setting




Q4. Do you personally order the Oncotype DX Breast Cancer Assay for your breast cancer patients with stage I/II, ER+, HER2-, and pN1mi (micrometastatic disease)?


By Specialty



Q5. For what percentage of your breast cancer patients with stage I/II, ER+, HER2- disease, with pN1mi (micrometastatic disease) have you personally ordered the Oncotype DX Breast Cancer Assay in the past year? (n = 458)




By Geography†




†Note: Percentages may not total 100 because of rounding

Q5. For what percentage of your breast cancer patients with stage I/II, ER+, HER2- disease, with pN1mi (micrometastatic disease) have you personally ordered the Oncotype DX Breast Cancer Assay in the past year?

By Practice Size†




By Practice Setting†



†Note: Percentages may not total 100 because of rounding

Q5. For what percentage of your breast cancer patients with stage I/II, ER+, HER2- disease, with pN1mi (micrometastatic disease) have you personally ordered the Oncotype DX Breast Cancer Assay in the past year?

By Specialty†



†Note: Percentages may not total 100 because of rounding

NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. NCCN Trends™ surveys are designed to reach targeted populations that can include several thousand clinicians as a potential sample size. NCCN can also provide analytics on existing NCCN Trends™ and clinician demographic data sets, allowing for greater insight into oncology practice patterns.

To commission an **NCCN Trends™** survey, to discuss analytic and data services, or to request information on other NCCN programs and resources, please contact:

Christine MacCracken, MSHEd, BSN
Director, Business Insights
215.690.0557
maccracken@nccn.org

National Comprehensive Cancer Network® (NCCN®)

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 21 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.



National
Comprehensive
Cancer
Network®

275 Commerce Drive • Suite 300
Fort Washington, PA, 19034
Telephone: 215.690.0300
Fax: 215.690.0280

NCCN.org - For Clinicians • NCCN.com - For Patients

*All NCCN Trends™ survey content and resulting data are owned by NCCN. Survey responses are made anonymous to protect the privacy of survey respondents. NCCN may license survey content, data, and analytic results to third parties, but retains the rights to use this data for other purposes, including the support of educational and research efforts or for other strategic or business purposes.